CA
NZ
UK
AU
IND
US
…
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biocure Technology Inc is a Canada-listed life-sciences company; public disclosures are limited, but it appears positioned in biotechnology and medical technologies. Long-term growth may depend on product development progress, regulatory approvals, strategic partnerships and access to capital, which could support commercialization prospects and potential upside for investors.
Key risks include limited public information, development and clinical/regulatory setbacks, significant capital requirements and low stock liquidity that could materially affect execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.10M | -0.26M | -1.49M | -0.40M | -1.15M |
| Minority interest | - | 0.00M | 0.03M | 0.06M | 0.02M |
| Net income | -0.10M | -0.26M | -1.81M | -1.45M | -1.13M |
| Selling general administrative | 0.06M | 0.32M | 0.33M | 0.67M | 2.34M |
| Reconciled depreciation | - | - | - | 0.02M | 0.08M |
| Ebit | - | - | - | - | -1.73M |
| Ebitda | - | - | - | -0.40M | -0.58M |
| Operating income | -0.09M | -0.34M | -1.08M | -0.69M | -3.90M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.00M | 0.50M |
| Interest income | - | - | - | - | 0.09M |
| Net interest income | -0.01M | -0.01M | -0.01M | -0.00M | -0.41M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 0.09M | 0.34M | 1.08M | 0.69M | 3.90M |
| Total other income expense net | -0.00M | 0.09M | -0.41M | 0.29M | 3.16M |
| Discontinued operations | - | - | - | - | 0.72M |
| Net income from continuing ops | -0.10M | -0.26M | -1.49M | -0.40M | -1.15M |
| Net income applicable to common shares | - | - | - | - | -1.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.01M | 1.99M | 1.98M | 2.08M | 4.15M |
| Intangible assets | - | - | - | 0.00M | 0.00M |
| Other current assets | - | - | - | 0.06M | 1.89M |
| Total liab | 0.44M | 0.65M | 0.37M | 4.06M | 5.01M |
| Total stockholder equity | 1.58M | 1.34M | 1.60M | -1.98M | -0.53M |
| Other current liab | - | - | - | 3.62M | - |
| Common stock | - | - | - | 18.45M | 18.38M |
| Capital stock | 18.01M | 17.68M | 17.68M | 18.45M | 18.38M |
| Retained earnings | -23.94M | -23.83M | -23.57M | -20.01M | -26.08M |
| Other assets | - | - | - | 0.00M | 0.04M |
| Cash | 0.04M | 0.02M | 0.00M | 0.04M | 0.16M |
| Total current liabilities | 0.44M | 0.60M | 0.33M | 4.41M | 3.75M |
| Net debt | 0.02M | 0.03M | 0.04M | 0.04M | 3.63M |
| Short term debt | - | - | - | 0.08M | 0.00M |
| Short long term debt | 0.06M | - | - | 0.08M | 2.53M |
| Other stockholder equity | - | - | - | -0.42M | 7.17M |
| Property plant equipment | - | - | - | 0.00M | 0.01M |
| Total current assets | 0.05M | 0.03M | 0.01M | 0.12M | 2.13M |
| Long term investments | 1.97M | 1.97M | 1.97M | 1.97M | 1.97M |
| Net tangible assets | - | - | - | - | -0.53M |
| Net receivables | - | - | - | 0.02M | 0.01M |
| Long term debt | - | 0.05M | 0.04M | 0.00M | 1.25M |
| Inventory | - | - | - | 0.00M | 0.00M |
| Accounts payable | 0.35M | 0.60M | 0.33M | 0.71M | 0.94M |
| Non current assets total | 1.97M | 1.97M | 1.97M | 1.97M | 2.02M |
| Capital lease obligations | - | - | - | 0.00M | 0.00M |
| Long term debt total | - | - | - | 0.00M | 1.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.04M | 0.07M | -0.00M |
| Change to liabilities | - | - | - | - | 0.30M |
| Total cashflows from investing activities | - | - | - | 0.07M | 0.03M |
| Net borrowings | - | 0.00M | -0.05M | 0.00M | 0.07M |
| Total cash from financing activities | 0.10M | 0.00M | -0.05M | 0.63M | 1.17M |
| Change to operating activities | - | - | - | - | -0.05M |
| Net income | -0.10M | -0.26M | -1.81M | -1.45M | -1.13M |
| Change in cash | 0.02M | 0.01M | -0.03M | -0.12M | 0.11M |
| Begin period cash flow | 0.02M | 0.00M | 0.04M | 0.16M | 0.05M |
| End period cash flow | 0.04M | 0.02M | 0.00M | 0.04M | 0.16M |
| Total cash from operating activities | -0.08M | 0.01M | -0.22M | -0.83M | -1.08M |
| Issuance of capital stock | 0.10M | - | - | 0.03M | 1.10M |
| Depreciation | - | - | - | 0.02M | 0.08M |
| Other cashflows from investing activities | - | - | - | 0.07M | 0.45M |
| Change to inventory | - | - | - | 0.00M | 0.00M |
| Change to account receivables | - | - | - | - | -0.01M |
| Sale purchase of stock | - | - | - | 0.00M | 0.99M |
| Other cashflows from financing activities | - | - | - | 0.63M | 0.24M |
| Change to netincome | - | - | - | - | -0.20M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.02M | 0.27M | 0.25M | 0.49M | 1.72M |
| Stock based compensation | - | - | - | 0.00M | 1.16M |
| Other non cash items | 0.01M | 0.01M | 0.01M | 0.01M | 0.27M |
| Free cash flow | -0.08M | 0.01M | -0.22M | -0.82M | -1.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences Inc |
0.06 0.19% |
32.18 | - | - | - | 13.50 | -0.10 |
| METX ME Therapeutics Holdings Inc. |
- -% |
1.05 | - | - | - | 72.00 | - |
| TELI Telescope Innovations Corp. |
- -% |
0.34 | - | - | 4.32 | 6.45 | -1.62 |
| DTC Defence Therapeutics Inc |
- -% |
0.31 | - | - | - | 89.80 | -9.99 |
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. Björn Cochlovius Ph.D. | President | NA |
| Mr. Konstantin Lichtenwald B.B.A., CPA, CGA | CFO, Corporate Secretary & Director | 1984 |
| Mr. Yee Sing Cheng | CEO & Director | 1981 |
| Mr. Marco Nonni | Consultant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...